Cleared Traditional

K124021 - ARKRAY GLUCOCARD 01 BLOOD GLUCOSE MONIT...

K124021 is the FDA 510(k) clearance for ARKRAY GLUCOCARD 01 BLOOD GLUCOSE MONIT... by Arkray Factory, Inc.. It is a Class 2 Chemistry device (product code CGA) cleared through the Traditional 510(k) pathway after a 550-day FDA review.

K124021 · Arkray Factory, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 2014
Decision
550d
Days
Class 2
Risk

K124021 is an FDA 510(k) clearance for the ARKRAY GLUCOCARD 01 BLOOD GLUCOSE MONITORING SYSTEM AND RELION CONFIRM BLOOD .... Classified as Glucose Oxidase, Glucose (product code CGA), Class II - Special Controls.

Submitted by Arkray Factory, Inc. (Edina, US). The FDA issued a Cleared decision on June 30, 2014 after a review of 550 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Arkray Factory, Inc. devices

Submission Details

510(k) Number K124021 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 27, 2012
Decision Date June 30, 2014
Days to Decision 550 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
462d slower than avg
Panel avg: 88d · This submission: 550d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CGA Glucose Oxidase, Glucose
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CGA Glucose Oxidase, Glucose

All 191
Devices cleared under the same product code (CGA) and FDA review panel - the closest regulatory comparables to K124021.
GEM Premier 3000
K161818 · Instrumentation Laboratory CO · Sep 2016
GAL-1F Blood Glucose Monitoring System, GAL-1F Pro Blood Glucose Monitoring System
K142689 · Apex BioTechnology Corp. · Aug 2015
MEG-2B Blood Glucose Monitoring System, MEG-2B Pro Blood Glucose Monitoring System
K143750 · Apex BioTechnology Corp. · May 2015
AUTOSURE HT BLOOD GLUCOSE MONITORING SYSTEM
K131750 · Apex BioTechnology Corp. · Mar 2014
ACON ON CALL VIVID PAL BLOOD GLUCOSE MONITORING SYSTEM
K122110 · ACON Laboratories, Inc. · Nov 2012
MEG-2B BLOOD GLUCOSE MONITORING SYSTEM, PRO BLOOD GLUCOSE MONITORING SYSTEM, BLOOD GLUCOSE TEST STRIPS, GLUCOSE CONTROL
K120448 · Apex BioTechnology Corp. · Apr 2012